Hillstream Biopharma (NASDAQ:CNTN) Announces Quarterly Earnings Results

Hillstream Biopharma (NASDAQ:CNTN) posted its earnings results on Wednesday. The company reported ($0.23) EPS for the quarter, FiscalAI reports.

Hillstream Biopharma Stock Performance

Shares of CNTN stock traded up $0.24 on Wednesday, hitting $3.51. The company had a trading volume of 640,162 shares, compared to its average volume of 780,302. The stock has a market cap of $198.86 million, a price-to-earnings ratio of -0.88 and a beta of 1.44. The company’s 50-day moving average price is $3.42. Hillstream Biopharma has a twelve month low of $1.08 and a twelve month high of $9.08.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CNTN shares. Wall Street Zen cut Hillstream Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Weiss Ratings started coverage on Hillstream Biopharma in a research note on Monday, March 9th. They issued a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Hillstream Biopharma presently has a consensus rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.